한국유니온제약
080720KOSDAQ62.8 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.
Number of Employees
123people
Average Salary
39.2M KRW
Score Calculation Basis
Detailed Financial Score
52.4x industry avg (excellent)
Half of industry avg (excellent)
Avg ▼23.9% (2-year basis)
Avg ▼92.6% (2-year basis)
Avg ROE 88.4% (improving, 3yr)
Detailed News Sentiment
- Positive부광약품 자회사 한국유니온제약, 법정관리 졸업…부채비율 40%대로
한국유니온제약의 부광약품 자회사 졸업으로 부채비율 감소와 흑자 전환 기대감이 높아져 긍정적 영향.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -11.56% (falling)
Volume flat
Detailed Disclosure
- Neutral주주명부폐쇄기간또는기준일설정2026-09-01
- Neutral주주총회소집결의 (임시주주총회)2026-09-01
- Neutral기타시장안내 (관리종목 지정 사유 일부 해제 관련 시장조치 미진행)2026-08-31
- Negative회생절차종결결정2026-08-31
- Neutral주권매매거래정지기간변경 (투자자 보호)2026-08-27
